The US Food and Drug Administration (FDA) has granted its clearance to EDDA Technology's new IQQA-BodyImaging product for imaging-guided cancer treatment, paving the way for its launch later this month.


A part of the IQQA Platform and Product Suite, the new system will be introduced at the upcoming 100th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, US.

According to the company, the new IQQA-BodyImaging extends the 3D features found in the IQQA product portfolio to thoracic, abdominal and pelvic multimodality scans.

EDDA Technology president and CEO: "We are pleased to announce the launch of IQQA-BodyImaging, which significantly broadens our product and service offering to cover close to 50% of the world’s cancer incidences.

"Our team at EDDA is committed to innovation to support the latest treatment options, including minimally invasive and robotic-assisted approaches, where information from imaging is essential for optimal treatment planning, guidance and confirmation."

The company, along with its clinical collaborator Massachusetts General Hospital, will also introduce the cloud-based OnDemand service for imaging-guided cancer treatment, at the event.

In addition, the firm will showcase IQQA-Liver Multimodality, which is currently being used for interactive treatment planning and post-procedural assessment of liver diseases.

The IQQA Platform and Product Suite has been developed for multiple stakeholders, including radiologists, interventional radiologists, surgeons, and oncologists.

Image: IQQA-BodyImaging for thoracic, abdominal,and pelvic applications of cancer treatment planning, monitoring and follow-up. Photo: courtesy of EDDA Technology, Inc.